Clinical Efficacy of Modified Sanzi Yangqintang and Colon Hydrotherapy on Treatment of Non-alcoholic Fatty Liver Disease with Phlegm-dampness

Kai-ping JIANG; Kai-zhou HUANG; Jian-hong LI; Teng-yu QIU; Xiao-ai MO; Hong-tao HU; Wen-qiang GUO; Jian REN; Lei ZHANG; Qing-hua HUANG; Ying ZUO; Hai-jun CUI; Xu-li CHEN

doi:10.13422/j.cnki.syfjx.20200326

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Modified Sanzi Yangqintang and Colon Hydrotherapy on Treatment of Non-alcoholic Fatty Liver Disease with Phlegm-dampness

Topic on TCM Clinical Exploration of Non-alcoholic Fatty Liver Disease | 更新时间：2021-02-09

- Clinical Efficacy of Modified Sanzi Yangqintang and Colon Hydrotherapy on Treatment of Non-alcoholic Fatty Liver Disease with Phlegm-dampness
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 3, Pages: 31-36(2020)
- 作者机构：
  
  佛山市中医院，广东佛山　 528000
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20200326
  CLC： R22; R242; R2-031;R287
- Published：05 February 2020，
  
  Published Online：17 October 2019，
  
  Received：24 September 2019，
- 稿件说明：
扫描看全文
Kai-ping JIANG, Kai-zhou HUANG, Jian-hong LI, et al. Clinical Efficacy of Modified Sanzi Yangqintang and Colon Hydrotherapy on Treatment of Non-alcoholic Fatty Liver Disease with Phlegm-dampness. [J]. Chinese Journal of Experimental Traditional Medical Formulae 26(3):31-36(2020)
DOI：

Kai-ping JIANG, Kai-zhou HUANG, Jian-hong LI, et al. Clinical Efficacy of Modified Sanzi Yangqintang and Colon Hydrotherapy on Treatment of Non-alcoholic Fatty Liver Disease with Phlegm-dampness. [J]. Chinese Journal of Experimental Traditional Medical Formulae 26(3):31-36(2020) DOI： 10.13422/j.cnki.syfjx.20200326.

摘要

目的：

探讨三子养亲汤加味结肠水疗治疗痰湿内阻型非酒精性脂肪性肝病(NAFLD)的临床疗效。

方法：

选取痰湿内阻型NAFLD患者100例，经随机数字表法分为治疗组和对照组，各50例。两组患者均予口服水飞蓟宾胶囊与甘草酸二胺胶囊为基础治疗，治疗组则在基础治疗上加用三子养亲汤加味结肠水疗，对照组则加用生理盐水结肠水疗，疗程均为7 d。记录两组患者治疗前后主要中医证候评分、肝脏酶学指标[丙氨酸氨基转氨酶(ALT)，天冬氨酸氨基转氨酶(AST)，

-谷氨酸转肽酶(GGT)]，血脂指标[胆固醇(TCH)，甘油三酯(TG)]

，炎症因子指标[白细胞介素-6(IL-6)，肿瘤坏死因子-

(TNF-

)]，FibroScan测量值[肝脏硬度值(LSM)，受控衰减参数(CAP)]

，尿酸及体质量的变化，并观察不良反应，评价患者的用药安全性。

结果：

与本组治疗前比较，两组患者治疗后中医证候评分，肝脏酶学指标，血脂指标，炎症因子指标，FibroScan CAP，尿酸，体质量均明显降低(

0.05

0.01)。治疗后两组在肝脏酶学指标，TCH，IL-6，LSM较对照组未见统计学差异，治疗后治疗组中医证候评分，UA，TNF-

，FibroScan CAP较对照组明显降低(

0.05)。

结论：

三子养亲汤加味结肠水疗，不仅能明显改善痰湿内阻型NAFLD的临床症状，而且还可显著降低TG，UA，TNF-

，FibroScan CAP及体质量，可在短期取得内取得一定的临床疗效。

Abstract

Objective:

To explore the clinical efficacy of modified Sanzi Yangqintang combined with colon hydrotherapy in the treatment of non-alcoholic fatty liver disease (NAFLD) with phlegm-dampness.

Method:

Totally 100 patients with NAFLD were selected and randomly divided into treatment group (50 cases) and control group (50 cases). Both groups were orally given silybin and glycyrrhizic acid diamine capsules.The treatment group was also added with modified Sanzi Yangqintang and colon hydrotherapy.The treatment lasted for 7 days.The control group was also added with saline colon hydrotherapy.Main traditional Chinese medicine (TCM) syndrome scores and liver function indexes before and after treatment [alanine aminotransferase (ALT)

aspartate aminotransferase (AST)

-glutamate transpeptidase (GGT)]

blood lipid routine [cholesterol (TCH)

triglyceride (TG)]

inflammatory factors [interleukin-6 (IL-6)

tumor necrosis factor-

(TNF-

)]

FibroScan measurement [liver stiffness measurement (LSM)

controlled attenuation parameters (CAP)]

uric acid and body weight changes were observed.Adverse reactions were observed

and the patient's medication safety was evaluated.

Result:

TCM syndrome score

liver enzyme index

blood lipid index

inflammatory factor index

FibroScan CAP

uric acid and body weight of the two groups were significantly reduced than those before treatment(

0.05

0.01) .There was no significant difference in liver enzymes

TCH

IL-6 and LSM between treatment group and control group.And TCM syndrome scores

TNF-

FibroScan CAP decreased were significantly different from control group (

0.05).

Conclusion:

Modified Sanzi Yangqintang combined with colon hydrotherapy can not only alleviate NAFLD with phlegm-dampness symptoms

but also significantly reduce triglyceride

tumor necrosis factor and FibroScan CAP and body mass

with certain clinical efficacy in a short term.

关键词

三子养亲汤加味中药结肠水疗非酒精性脂肪性肝病痰湿内阻证

Keywords

modified Sanzi YangqintangChinese medicine colon hydrotherapynon-alcoholic fatty liver diseasephlegm-dampness

references

M E Rinella．Nonalcoholic fatty liver disease：a systemic review[J]．JAMA，2015，313(22)：2263-2272.

Z M Younossi, A B Koenig, D Abdelatif, et al.Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes[J]．Hepatology, 2016, 64(1): 73-84.

Z Z LI, J XUE, P CHEN, et al.Prevalence of nonalcoholic fatty liver disease in mainland of China: a Meta-analysis of published studies[J]．J Gastroenterol Hepatol, 2014, 29(1): 42-51.

F S WANG，J G FAN，Z ZHANG，et al.The global burden of liver disease：the major impact of China[J]．Hepatology，2014，61(6)：2099-2108.

J G FAN，S U Kim，V W WONG．New trends on obesity and NAFLD in Asia[J]．J Hepatol，2017，67(4)：862-873.

张声生，李军祥．非酒精性脂肪性肝病中医诊疗专家共识意见(2017)[J]．中医杂志，2017，58(19): 1706-1710.

李红，刘璇，陈斌，等．长沙地区1386例非酒精性脂肪性肝病患者中医体质分布特征及其与血压、体重指数、血脂、肝功能酶学的相关性研究[J]．中西医结合肝病杂志，2016，26(5)：263-266.

林立，梁惠卿，陈少东，等．非酒精性脂肪肝同病异证与肝活检病理学的相关性研究[J]．中华中医药杂志，2019，34(4)：1462-1465.

范建高．非酒精性脂肪性肝病诊疗指南(2010年修订版)[J]．胃肠病学和肝病学杂志，2010, 19(6): 483-487.

蒋开平，李建鸿，胡洪涛，等．慢性乙型肝炎湿热蕴结证和肝郁脾虚证患者肝纤维化Fi-broScan测定与肝组织病理学诊断的比较[J]．世界华人消化杂志，2014，22(19)：2768-2773.

史晓伟，王一强，张玉香，等．清肝祛湿活血方治疗非酒精性脂肪肝的疗效评价[J]．中国实验方剂学杂志，2016，22(15)：181-184.

康学东，党晓娟，王苑铭，等．化浊颗粒治疗2型糖尿病合并非酒精性脂肪肝(痰湿困脾型)[J]．中国实验方剂学杂志，2016，22(1)：171-175.

吕佳，江云，张鑫，等．非酒精性脂肪性肝病中医研究进展[J]．上海中医药杂志，2017，51(S1)：238-241.

朱金照，冷恩仁，桂先勇，等．白术、藿香等中药对胃排空、肠推进影响的实验研究[J]．中国中医基础医学杂志，2000，6(1)：24-26.

张国侠，盖国忠．莱菔子总生物碱对Apo E基因敲除小鼠血脂的影响[J]．中国老年学杂志，2010，30(6)：844-845.

耿芹，郑床木，管政，等．代谢组学法评价紫苏子抗小鼠急性肝损伤的作用[J]．食品科学，2014，35(17): 260-265.

朴颖，费宏扬，权海燕．紫苏叶提取物对肥胖小鼠的影响及作用机制[J]．中华中医药杂志，2017, 32(9)：3992-3996.

高冰冰，苏洁，王楠楠，等．复方紫苏子提取物对高脂血症模型大鼠血脂、肝脂及肝脏病变的影响[J]．浙江中医杂志，2016，51(5)：332-334.

曹思，常欣峰，尹宝，等．白芥子药组对肝纤维化大鼠的治疗作用及机制探讨[J]．时珍国医国药，2017，28(2)：265-268.

周喜丹，唐力英，周国洪，等．南北葶苈子的最新研究进展[J]．中国中药杂志，2014，39(24)：4699-4708.

E Buzzetti, M Pinzani, E A Tsochatzis．The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]．Metabolism, 2016, 65(8): 1038-1048.

J YU, S Marsh, J HU, et al.The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background[J]．Gastroenterol Res Pract，2016，doi：10.1155/2016/2862173http://dx.doi.org/10.1155/2016/2862173.

翁小刚，朱晓新，杨庆，等．非酒精性脂肪肝的实验研究进展[J]．中国实验方剂学杂志，2009, 15(11)：104-109.

X Y ZHENG, L L GONG, R LUO, et al.Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J]．Lipids Health Dis，2017，16(10)：202.

谢伶俐，周力，李丽滨，等．TNF-α和IL-6在非酒精性脂肪性肝病患者血清中的水平及意义[J]．世界华人消化杂志，2010，18(14)：1492-1496.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Baihe Wuyaotang Ameliorates NAFLD by Enhancing mTOR-mediated Liver Autophagy

Mechanism of Astragaloside Ⅳ on db/db Mice with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease Based on AMPK Signaling Pathway

Effect of Zuogui Jiangtang Qinggan Prescription on Glucose and Lipid Metabolism in MKR Mice with Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease

Molecular Mechanism of Resveratrol Against NAFLD Based on Network Pharmacology

Related Author

QI Yajuan

WANG Rui

BAN Tiantian

XUE Lihui

FENG Xinyi

GUO Jiyuan

LI Jiaqi

HAN Xiaolei

Related Institution

School of Pharmacy， North China University of Science and Technology

Qian'an Hospital of Chinese Medicine

Comprehensive Test and Analysis Center， North China University of Science and Technology

North China University of Science and Technology Affiliated Hospital

School of Public Health， North China University of Science and Technology

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰